Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Farmers Insurance
Medtronic
Citi
Boehringer Ingelheim
Chubb
AstraZeneca
Dow
UBS

Generated: April 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,623,920

« Back to Dashboard

Which drugs does patent 8,623,920 protect, and when does it expire?

Patent 8,623,920 protects ZIPSOR and is included in one NDA.
Summary for Patent: 8,623,920
Title:Method of treating post-surgical acute pain
Abstract: A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.
Inventor(s): Kowalski; Mark M. (Winchester, MA), Young; James L. (Valley Park, MO), Moore; Keith A. (Loveland, OH)
Assignee: Depomed, Inc. (Newark, CA)
Application Number:13/205,033
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Drugs Protected by US Patent 8,623,920

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Depomed Inc ZIPSOR diclofenac potassium CAPSULE;ORAL 022202-001 Jun 16, 2009 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,623,920

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,939,518 Method of treating post-surgical acute pain ➤ Try a Free Trial
8,110,606 Method of treating post-surgical acute pain ➤ Try a Free Trial
7,662,858 Method of treating post-surgical acute pain ➤ Try a Free Trial
9,561,200 Method of treating post-surgical acute pain ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Fuji
Queensland Health
Chubb
Federal Trade Commission
Colorcon
AstraZeneca
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.